Fibrates plus betaine: A winning combination?

New Zealand Medical Journal

Volumn 123, Issue 1324, 2010, Pages 74-78

  Lever, Michael ^a   George, Peter M ^a   Slow, Sandy ^a   Elmslie, Jane L ^a   Shand, Brett I ^b   Scott, Russell S ^b   Chambers, Stephen T ^c  

^a CANTERBURY HEALTH LABORATORIES   (New Zealand)

^b CANTERBURY DISTRICT HEALTH BOARD   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETAINE; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTILIPEMIC AGENT; CLOFIBRIC ACID; LIPOTROPIC AGENT;

CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; METABOLIC SYNDROME X; NUTRITIONAL SUPPORT; OSMOREGULATION; REVIEW; SUGAR BEET; DRUG COMBINATION; HYPERLIPIDEMIAS; METABOLISM; TREATMENT OUTCOME;

BETAINE; CLOFIBRIC ACID; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPOTROPIC AGENTS; TREATMENT OUTCOME;

EID: 77958043069     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Benatar JR, Stewart RA. Is it time to stop treating dyslipidaemia with fibrates? N Z Med J. 2007;120(1261). http://www.nzma.org.nz/journal/120-1261/ 2706/content.pdf
2. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99[suppl]:3C-18C.
3. Brown WV. Expert Commentary: The safety of fibrates in lipid-lowering therapy. Am J Cardiol. 2007;99[suppl]:19C-21C.
4. Brinton EA. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio? Curr Atheroscler Rep. 2008;10:25-32.
5. Barter PJ, Rye K-A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol. 2008;28:39-46.
6. Tziomalos K, Atyhros VG, Karagiannis A, et al. Triglycerides and vascular risk: Insights from epidemiological data and interventional studies. Current Drug Targets. 2009;10:320-7.
7. Rosenson RS. Management of non-high-density lipoprotein abnormalities. Atherosclerosis. 2009;207:328-35.
8. Reiner Ž. Combined therapy in the treatment of dyslipidemia. Fundament Clin Pharmacol. 2010;24:19-28.
9. Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res. 2008;5:319-35.
10. Hottelart C, El Esper N, Archard JM, et al. Fenofibrate increases blood creatinine, but dies not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie. 1999;20:41-4.
11. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61.
12. Ansquer JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45:485-93.
13. Taskinen M-R, Sullivan DR, Ehnholm C, et al. Relationships of HDL Cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol. 2009;29:950-5.
14. Lacut K, Le Gal G, Abalain J-H, et al. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: Role of drug induced homocysteinemia? Thrombosis Res. 2008;122:314-9.
15. Lever M, George PM, Slow S, Elmslie JL, Scott RS, Richards AM, Fink JN, Chambers ST. Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovasc Drugs Ther. 2009;23:395-401.
16. Lever M, Slow S. The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism. Clin Biochem. 2010;43:732-744.
17. Lever M, George PM, Dellow WJ, Scott RS, Chambers ST. Homocysteine, glycine betaine, and N,N-dimethylglycine in patients attending a lipid clinic. Metabolism. 2005;54:1-14.
18. Slow S, Donnaggio M, Cressey PJ, Lever M, George PM, Chambers ST. The betaine content of New Zealand foods and estimated intake in the New Zealand diet. J Food Comp Anal. 2005;18:473-85.
19. Craig SAS, Betaine in human nutrition. Am J Clin Nutr. 2004;80:539-49.
20. Atkinson A, Slow S, Elmslie J, Lever M, Chambers ST, George PM. Dietary and supplementary betaine: effects on betaine and homocysteine concentrations in males. Nutr Metab Cardiovasc Dis. 2009;19:767-73.
21. Eklund M, Bauer E, Wamatu J, Mosenthin R. Potential nutritional and physiological functions of betaine in livestock. Nutr Res Rev. 2005;18:31-48.
22. Ratriyanto A, Mosenthin R, Bauer E, Eklund M. Metabolic, osmoregulatory and nutritional functions of betaine in monogastric animals. Asian-Austral J Animal Sci 2009;22:1461-76.
23. Konstantinova SV, Tell GS, Vollset SE, et al. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr. 2008;138:914-20.
24. Schwab U, Törrönen A, Toppinen L, et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr. 2002;76:961-7.
25. Olthof MR, van Vliet T, Boelsma E, Verhoef P. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr. 2003;133:4135-8.
26. Steenge GR, Verhoef P, Katan MB. Betaine supplementation lowers plasma homocysteine in healthy men and women. J Nutr. 2003;133:1291-5.
27. Olthof MR, Verhoef P. Effect of betaine intake on plasma homocysteine concentrations and consequences for health. Current Drug Metab. 2005;6:15-22.
28. Armstrong LE, Casa DJ, Roti MW, et al. Influence of betaine consumption on strenuous running and sprinting in a hot environment. J Strength Cond Res. 2008;22:851-60.
29. Hoffman J, Ratamess N, Kang J, et al. Effect of betaine supplementation on power performance and fatigue. J Internat Soc Sports Nutr. 2009;6:7.